ANDA 203612, held by MCPRF. Fludeoxyglucose F-18.
As of Nov 21, 2026, ANDA 203612 (Fludeoxyglucose F18), held by MCPRF, was first approved by FDA on Aug 5, 2013, with 0 approved supplements and 0 published complete response letters.
Fludeoxyglucose F 18 Injection USP is indicated for positron emission tomography (PET) imaging in the following settings:
| Date | Submission | Status | Documents |
|---|---|---|---|
| Aug 5, 2013 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Fludeoxyglucose F1820-240mCi/ML · injectable;intravenous | Fludeoxyglucose F-18 | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters